key: cord-0699867-4dq30ze6
authors: Karas, Pamela L.; Rankin, Nicole M.; Stone, Emily
title: Medicolegal Considerations in Multidisciplinary Cancer Care
date: 2020-07-03
journal: JTO clinical and research reports
DOI: 10.1016/j.jtocrr.2020.100073
sha: 7bab4832c79b38bcf5e00ea84e4835920551cadb
doc_id: 699867
cord_uid: 4dq30ze6

Abstract Health professionals participating in multidisciplinary team (MDT) cancer meetings may not be aware of their medicolegal obligations. This commentary aims to identify medicolegal issues concerning multidisciplinary cancer care and provides recommendations for future implementation. Predominant medicolegal issues related to MDT care were identified in the literature and include: patient consent and privacy at MDT meeting, professional liability, formal expression of dissenting views, and duty of care. Analysis of the literature prioritises several recommendations for managing these issues. With limited precedent on which to base recommendations, this article identifies the formative evidence that may guide management of these issues in future MDT practice.

Multidisciplinary team (MDT) care in cancer medicine has become widely recognised as part of best practice management (Evans, Zorbas et al. 2008 , National Collaborating Centre for Cancer 2011 . MDT care is recommended by many guidelines and statutory bodies in North America, Europe and Australia (Sidhom and Poulsen 2006 , National Collaborating Centre for Cancer 2011 , Powell and Baldwin 2014 , NCCN Clinical Practice Guidelines in Oncology 2017 . Central to this approach is the MDT meeting or tumour board, where experts from each field generate a consensus treatment recommendation (Munro, Brown et al. 2015) . MDT care is associated with improved survival, timeliness of treatment and adherence to guidelines (Murray, O'Brien et al. 2003 , Conron, Phuah et al. 2007 , Leo, Venissac et al. 2007 , Sidhom and Poulsen 2008 , Freeman, Van Woerkom et al. 2010 , Boxer, Vinod et al. 2011 ). Relatively few clear policies stipulate the essentials of MDT practice. As one example, the European Partnership for Action Against Cancer (EPAAC) identified five core areas in cancer care organisation: care objectives, organisation, clinical assessment, patients' rights and empowerment and policy support (National Collaborating Centre for Cancer 2011).

Legal requirements of MDT care have not been extensively described or standardized. In a review of head and neck cancer MDT care, survey data from pharmaceutical company employees in 29 countries identified guidelines for MDT implementation in a number of countries, with specific legal information only publicly available in France (Licitra, Keilholz et al. 2016 ). Mandatory components of MDT meetings in France, include a statement of organization, minutes of each meeting and at least twice monthly schedule (Deneuve, Babin et al. 2015) . A lack of information about medicolegal implications of MDT decision making was identified in expert forums in Australia (National Breast Cancer Centre 2006) .

Related to the lack of both clinical and legal framework is clinician concern about the medicolegal implications of MDT care, which may act as a barrier to implementation (Evans, Zorbas et al. 2008 , Powell and Baldwin 2014 , Licitra, Keilholz et al. 2016 . Not only are there medicolegal concerns over team-based decisions, but also issues about potential conflicts of opinion with other members. An Australian survey study revealed that doctors participating in MDT meetings may not completely appreciate their legal responsibilities and potential liability generated against their involvement (Horvath, Yordan et al. 2010) . Only 48% of doctors believed they were individually liable for decisions made by the MDT meetings. More concerningly, even though 85% of doctors disagreed with the final MDT meeting decision at some time, 71% did not formally dissent on those occasions. These ideas contradict the purposes of multidisciplinary care to decrease the medicolegal risk; it has been found that MDTs lead to improved documentation, communication and timeliness to diagnosis and treatment, which are the leading causes of litigation in cancer care (Connolly 2004 ).

This commentary aims to identify the key medicolegal issues concerning the MDT approach in cancer as well as review recommendations for implementation. The search strategy for this review was conducted on Medline using OVID interface and PubMed databases with the following search terms: ("legal issues" OR "legal considerations" OR "medicolegal") AND ("multidisciplinary care" OR "multidisciplinary team" OR "tumor board") AND ("cancer" OR "cancer care" OR "tumour" OR "oncology"). This yielded nine peer-reviewed journal articles in total. Two of these were included based on the relevance to the study aims, while the remaining seven articles were excluded due to lack of content about medicolegal issues. We also hand searched the reference lists of the 21 papers, which yielded an additional 17 relevant articles.

Three publications addressed the issues of managing patient consent and privacy as key issues for MDTs.

A consensus statement from a national Australian forum proposed that patients discussed at MDTs are protected by the same principles governing doctor-patient confidentiality as occurs in individual consultations (Evans, Zorbas et al. 2008) . While it was deemed it unnecessary to deidentify patients during MDT discussions, the MDT members should have an opportunity to declare conflict of interest and opt-out of decision making. It also recommended that patient consent should always be obtained before a referral to the MDT meeting takes place, regardless of whether the patient will be billed by clinicians for case discussion. This is the responsibility of the treating clinician, although may be delegated to another team member. Informed consent requires that; (a) patients understand the purpose of the MDT meeting, (b) they are aware of the disciplines that may participate, (c) those who will be present in an observational capacity, and (d) what information about their medical history will be shared.

An Australian audit of 51 hospital MDTs across a range of tumour streams (breast, gynaecological, lung, prostate and colorectal) found that one-third of patients were not informed their case would be discussed by the MDT (Wilcoxon, Luxford et al. 2011 ).

Furthermore, patient consent was not sought for half of all cases discussed. Similarly, a 2015 survey of 37 MDTs found in that mostly verbal consent was elicited and it was rarely written in the medical file (Rankin, Lai et al. 2018) .

1) Informed consent should be obtained, either written or verbal, and documented in the patient's medical record before their case is discussed at an MDT meeting.

2) Patients do not need to be de-identified during MDT discussions. However, due diligence should be exercised to ensure patients' confidentiality is maintained outside the meeting setting.

Six publications addressed the issue of duty of care and whether it is shared by all MDT meeting attendees.

In North America (predominantly a common law system), a study indicated that through a formal referral process, the consulted doctor assumes a duty of care to the patient (Olick and Bergus 2003) . The court considers the following when determining whether a referral is formal;

(a) the existence of a written referral, (b) the extent of the information given to the specialist, (c) the awareness of the patient about the referral, (d) whether the advice will generally be relied on, (e) whether the referral and subsequent advice is documented, and (f) whether the specialist is paid for the consultation. If these are fulfilled, then the consulted doctor owes a duty of care to the patient; a failure to provide careful advice renders that doctor liable to direct action in negligence brought by the patient.

In Australia (a common law system), a study suggested that all doctors present at an MDT meeting would be deemed to owe a duty of care to the patients discussed, according to the law (Sidhom and Poulsen 2006) . This duty of care arises when the treating physician refers the patient to the MDT meeting doctors. Normally, when a patient is formally referred to a doctor, the latter assumes a duty of care for that patient. Most oncology MDT meetings would be regarded as a formal referral process that gives rise to a duty of care for each individual doctor.

A consensus statement from a national Australian workshop proposed that all doctors participating in MDT meetings should be aware that they owe a duty of care to all patients that are discussed, despite no personal contact with the patient (Evans, Zorbas et al. 2008) . It was noted that non-participating team members who are present in an observational capacity should not share the duty of care responsibility for recommendations made at the MDT meetings. For this purpose, it is recommended that, for each case discussed, the identity of the team members who contributed to the discussion and decision-making process is documented in the medical record.

Beyond the MDT meeting, an international study stated that the referring physician is responsible for discussing the team's treatment recommendation with the patient following a decision (Licitra, Keilholz et al. 2016 ). This discussion should clearly state the goals of treatment, likely outcomes and potential side effects, as well as any other pertinent information that arose during the MDT meeting.

In France (a civil law system), if the treating physician deviates from the plan proposed by the MDT, they are required by law to clearly record the justification for this in the patient's file (Deneuve, Babin et al. 2015) . In Germany (also a civil law system), while the recommendations of the MDT meeting are not legally binding, physicians are obliged to critically review the recommendations prior to their implementation (Haier and Bergmann 2013) . However, the physician must be able to justify a failure to comply with these recommendations on the basis of medical due diligence.

Clearly, documentation of the MDT meeting discussion is important; it provides a constant reminder to each doctor that they are individually responsible for the team decision (Sidhom and Poulsen 2006) . The meeting outcome should be clearly documented in the patient's medical record and communicated to the treating physician. Ideally, the treating physician is present, as this is the most important factor to ensure adherence to the treatment plan (Basta, Baur et al. 2016 ).

Documentation varies between MDT meetings; some of the variables recorded may include presence or absence of specialty physicians, presence of treating physician, duration of the meeting, patient follow-up, need for additional imaging and, change of referral diagnosis or treatment (Basta, Baur et al. 2016) . The use of a template was reported in an audit of multidisciplinary breast cancer meetings in the USA and shown to increase adherence rates to national guidelines (Farrugia, Fischer et al. 2015) . Similarly, a template to report MDT members present and treatment recommendations to general practitioners has been pilot tests in Australian lung cancer MDTs (Rankin, Collett et al. 2017 ). In addition, an audit of tumor boards in the United Kingdom (UK) reported that 97.1% of their discussions were clearly and accurately documented (De Ieso, Coward et al. 2013 ). The authors revealed that a strict review of the electronic record by secretarial staff and MDT meeting coordinators occurred following MDT meetings, as well as subsequent communication with those responsible for documenting decisions within 48 hours of the meeting. The authors also found the introduction of a proforma to improve documentation.

3) For each case discussed, members of the MDT meeting who contribute to the treatment plan and decision-making process should be identified and recorded, as they have a duty of care to the patient.

recorded in the patient record and communicated with the patient's referring practitioner in a timely way, which may be the General Practitioner in some cases.

Not all MDT meeting attendees will be involved in the patient's care. This introduces the question of who would be liable if a patient suffered harm because of the agreed treatment and brought a negligence case in relation to their care (Evans, Zorbas et al. 2008) . Traditionally, medical law assigns responsibility to individuals and not to groups. No such case in which negligence proceedings have been brought against an MDT rather than individual clinicians or hospital have not widely been reported in any common-law country. Four papers addressed the issue of professional liability.

One author (Sharpe 2000) suggested that any group decision must be considered to have been made based on individual opinions of the doctor's present. Thus, doctors attending the MDT meetings are deemed to have been personally consulted about the patient and have come to the same decision as a group, even if that doctor did not speak during the meeting.

Another paper discussed the fact that an MDT meeting group has no official legal identity that itself can act, and hence attract, liability for any negligence (Sidhom and Poulsen 2006) . This raised the question of who would be liable if a patient suffered harm because of an agreed decision.

In Australia, one study found that one-quarter of the MDT's recommended treatment plan was not noted in the patient record (Wilcoxon, Luxford et al. 2011) . In France, legal requirements govern MDT practices and the opinion of the MDT, including the therapeutic plan and the name and qualifications of the participants, must be recorded in the patient's medical record (Deneuve, Babin et al. 2015) . In Germany, documentation of MDT meetings has the same requirements as any other consultation work (Haier and Bergmann 2013) .

5) Doctors who contribute to a treatment recommendation within an MDT meeting share responsibility for the decisions within their area of expertise and could be liable if a negligence case is brought by a patient. That clinician may be held legally responsible for decisions made within their field.

There are some instances in the literature about how dissenting views are expressed within MDT meetings. For example, a study of 461 lung cancer specialists in North America, when asked their personal preference for treatment if they were to develop lung cancer, there was no consensus as to their preferred treatment in either of two clinical situations (Palmer, O'Sullivan et al. 1990 ). Equally, no single medical professional can possess the necessary background to make optimal treatment decisions independently or avoid inevitable unconscious bias toward their own area of expertise (Licitra, Keilholz et al. 2016) .

MDT meetings may not completely appreciate their legal responsibilities and potential liability generated against their involvement (Sidhom and Poulsen 2008) . Only 48% of doctors believed they were individually liable for decisions made by the MDT meetings. This study also indicated that even though 85% of doctors disagreed with the final MDT meeting decision at some time, 71% did not formally dissent on those occasions.

A French study revealed that disagreements were most often related to; (a) lack of answers in the evidence base for more complex case leading to multiple potential treatments, (b) different interpretations of technical feasibility amongst surgeons, and (c) a lack of consideration of the patient's wishes (Molyneux 2001 ).

Awareness of their legal responsibilities should encourage an effort to fully explore all of the members opinions during MDT meetings and ensure that no individual or speciality dominates the decision-making at the expense of others (National Breast Cancer Centre 2006) . If any doctor feels that their opinion has not be considered appropriately, or if they disagree with the final decision, they should formally dissent and have this recorded to remove responsibility for that decision (Evans, Zorbas et al. 2008) . Ideally, each doctor should document their agreement, disagreement or abstention from each decision made at the meeting. It has been suggested that where appropriate differences of opinions about treatment occur, it is important that options are communicated to the patient in an unbiased way. In the UK (a common law system), lung cancer MDT meetings at district general hospital in Southend incorporated a tertiary cardiothoracic centre in London via videoconferencing (Davison, Eraut et al. 2004) . It was found that annual resection rates increased by 30% following introduction of telemedicine MDT meetings, and the mean time from first being seen in clinic to surgery was reduced from 69 to 54 days. Shorter evaluation time before definitive treatment plan with videoconferencing also reported by Stevenson et al. (2013) for lung cancer MDTs in USA and Chekerov et al. (2008) for gynaecological cancer in Germany.

An Australian study of videoconferencing of multidisciplinary breast cancer meetings between three public hospitals demonstrated increased attendance (Delaney, Jacob et al. 2004 ). There were, however, fewer cases discussed overall and the "formal and regimented" approach via videoconferencing precluded vigorous case discussions. Nonetheless, clinical practice guidelines for teleoncology have been developed by the Clinical Oncology Society of Australia (COSA 2020), which promote MDT care for patients in rural and remote areas.

The issues of patient confidentiality and privacy remain the primary concern of widespread implementation of these systems. To maintain privacy, availability of adequate information infrastructure that is highly secure is the most challenging obstacle. While various unsecure web-based platforms continued to be used, higher standards for consent and privacy are hospitals in Japan (a civil law system). Staff were given access to a high-security communication line and able to share patient information in real time. In order to maintain patient privacy, access to the software was password protected, it was separated from the internet and patient anonymity was maintained. Such standards should be a minimum for other web-based platform used, otherwise patient privacy cannot be guaranteed.

The authors acknowledge the limited number of peer-reviewed articles discussing the medicolegal issues that arise in MDT cancer care. As this was not a systematic review, it is possible that we did not locate all studies relevant to the topic. Future work focussing on the experience of MDTs in identifying and managing medicolegal issues is warranted. Specifically, exploring strategies to overcome these issues within a team-based approach is needed, which may then be implemented into daily practice.

Clinicians participating in MDT meetings may not completely understand their medicolegal obligations, which may pose barriers to their full participation in MDT meetings. Predominant medicolegal issues related to MDT care include patient consent and privacy at MDT meetings, professional liability, formal expression of dissenting views, and duty of care. With limited precedent on which to base recommendations around managing these, this review serves to identify formative evidence that may guide management of these issues in future MDT practice. 

Is there a Benefit of Multidisciplinary Cancer Team Meetings for Patients with Gastrointestinal Malignancies?

Do multidisciplinary team meetings make a difference in the management of lung cancer

Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany

Managing patient consent in multidisciplinary team environment -KJ v Wentworth Area Health Service and its implications for HRIPA

Analysis of multidisciplinary lung cancer practice

Clinical practice guidelines for teleoncology

Telemedicine for multidisciplinary lung cancer meetings

A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology

Comparison of face-toface and videoconferenced multidisciplinary clinical meetings

Guidelines (short version) of the French Otorhinolaryngology -Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making process

A statewide community cancer center videoconferencing program

Medicolegal implications of a multidisciplinary approach to cancer care: consensus recommendations from a national workshop

Improved Breast Cancer Care Quality Metrics After Implementation of a Standardized Tumor Board Documentation Template

The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer

Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics

Multidisciplinary management of lung cancer: how to test its efficacy?

Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer

Interprofessional teamworking: what makes teams work well?

Do Multidisciplinary Team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience

The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised twostop pathway

Non-Small Cell Lung Cancer Version 8

Malpractice liability for informal consultations

Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study

Multidisciplinary team management in thoracic oncology: more than just a concept?

Implementation of a lung cancer multidisciplinary team standardised template for reporting to general practitioners: a mixed-method study

Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change

Behind closed doors: accountability and responsibility in patient care

Group decisions in oncology: doctors' perceptions of the legal responsibilities arising from multidisciplinary meetings

Multidisciplinary care in oncology: medicolegal implications of group decisions

Development of a virtual multidisciplinary lung cancer tumor board in a community setting

Multidisciplinary Lung Cancer Tumor Board Connecting Eight General Hospitals in Japan via a High-Security Communication Line

Multidisciplinary cancer care in Australia: a national audit highlights gaps in care and medico-legal risk for clinicians